

**ASX RELEASE**

**6 May 2021**

**ASX: NVU**

## **Nanoveu to Pursue US Sales with EPA Approval**

### **Highlights:**

- **MoU signed for active ingredients within Nanoshield to be sourced from US-based specialised copper supplier Cupron Materials**
- **Cupron's existing EPA Registration allows Nanoveu expansion into the US with Nanoshield antimicrobial films**
- **Nanoveu now approved to market the antimicrobial effects of Nanoshield in the US**

Nanoveu Limited ("Nanoveu" or the "Company") is pleased to announce it has signed a memorandum of understanding (MoU) for twelve-month non-exclusive supply of copper iodide metal powder or "Cupron Enhanced Product" (CEP) for use in Nanoshield antiviral and antimicrobial products sold in the USA.

The Nanoshield product, which is a protective film employing a transparent resin with activated copper, is capable of using Cupron's CEP without affecting efficacy or production profile.

Importantly, the CEP material is registered under the United States Environmental Protection Agency (EPA). The agreement allows Nanoveu to sell its Nanoshield product (using CEP) under Cupron's EPA Registration.

Cupron's EPA approval permits products using CEP to make a number of claims, including the provision of antimicrobial protection, prevention of bacteria, fungi, mould and mildew growth, and the ability to keep surfaces cleaner for longer periods.

Cupron will also endeavour to receive approval from the EPA for a new Public Health Claim – relating to antiviral properties – based on Cupron's existing EPA Registration.

### **Commenting on the MoU, Nanoveu Executive Chairman and CEO Alfred Chong said:**

"This is a particularly important MoU which will see Nanoveu increase its avenues to generate sales in the massive market of the USA.

"The use of Cupron's material will allow us much greater flexibility in the way the product is applied and marketed. It also opens up a host of new areas that is only possible with regulatory approval.

"To date, we have been unable to make public health claims within the US. Now that the materials we are using are EPA approved we are able to better market Nanoshield, making claims about its antimicrobial properties. These claims are justified based on the rigorous testing applied to the product thus far.

"Cupron have established a prestigious name in the USA and it is exceptionally pleasing that we are able to apply our own processing techniques to their copper-based product without any substantive change to Nanoshield."

Cupron is a copper-based antimicrobial technology company based in Delaware, USA which harnesses the unique properties of copper for healthcare, consumer, industrial, and military applications.

The supplier's technology has been developed over a period of decades and is now used in a number of medical textile settings, such as socks with anti-fungal properties, antimicrobial hospital bed linen and has developed adult diapers for use in retail channels in Israel through a partnership with global personal-care brand Kimberly-Clark.

Cupron's patented and proprietary embedded copper technology has earned multiple, unique public health claims from the US Environmental Protection Agency, and additional innovations are in development.

Under the MoU, Nanoveu will be offered a fixed price for CEP material with Cupron receiving a sales royalty on US-based Nanoshield sales of 8% for the first US\$1 million sales, 6% for US\$1-10 million in sales and 4% of all sales thereafter.

Nanoveu's antiviral technology has been independently demonstrated to be a highly effective agent for the eradication of viruses. The technology has been proven to eliminate 99.99%<sup>1</sup> of OC43, a viral strain affecting humans that is also a surrogate for COVID-19, in 30 minutes. The antiviral protection has also been validated against other bacteria and viruses including e.Coli, Influenza A (subtype H3N2), and coronavirus MHV-A59<sup>2</sup>. Additionally, testing simulating 12 months outside weather conditions has found Nanoveu's products retain their effectiveness against MS2 Bacteriophage, a single-strand RNA virus<sup>3</sup>.

- Ends -

This announcement has been authorised for release by Nanoveu's Executive Chairman and CEO.

**For further information, please contact:**

**Alfred Chong**  
**Executive Chairman and CEO**

t: +65 6557 0155  
e: info@nanoveu.com

**For media / investor enquiries, please contact:**

**David Tasker / Alex Baker**  
**Chapter One Advisors**

t: + 61 433 112 936 / +61 432 801 745  
e: dtasker@chapteroneadvisors.com.au

---

<sup>1</sup> See announcements of 5 and 25 May 2020

<sup>2</sup> See announcement of 15 April 2020

<sup>3</sup> See ASX announcement of 18 February 2021



### **About Nanoveu:**

Nanoveu is a technology company developing a range of products for mobile phones and other digital displays. The Company's wholly-owned, flagship product is its Nanoshield antiviral protection which is available in a variety of mobile phone screen covers, mobile phone cases and as a commercial film capable of being applied to a number of surfaces. The product is a clear plastic containing a layer of charged copper nanoparticles which have antiviral and antimicrobial properties. The product is commercially available and sold in a number of countries via Nanoveu's channel partners. Nanoveu also produces EyeFly3D™, which converts 2D digital displays into 3D without the need for 3D glasses and is currently available for Apple iPhones and Google Pixel 3 phones.

In addition, the Company is also developing the following products:

- Customskins: vending machines capable of precisely applying screen covers to mobile phones in just over a minute and with an alignment accuracy of 150 microns;
- EyeFyx: a vision correction solution under development using hardware and software to manipulate screen output; and
- Anti-reflective coating technology capable of being applied to mobile phones, tablets, automotive displays and other digital displays.